<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134832">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346410</url>
  </required_header>
  <id_info>
    <org_study_id>08-060</org_study_id>
    <nct_id>NCT01346410</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer</brief_title>
  <official_title>Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. John's Mercy Research Institute, St. Louis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. John's Mercy Research Institute, St. Louis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the local control rate as well as acute and late toxicity rates of
      stereotactic body radiotherapy (SBRT) for the treatment of unresectable pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single institution, non-randomized, prospective, phase IV trial of SBRT for
      unresectable pancreatic cancer.

      Data collected will include patient demographics, pathology data, tumor stage, SBRT dose
      fractionation scheme, dose received by adjacent critical normal tissues, tumor recurrence
      data, and acute and late toxicities.

      Follow up data will be collected during the patient's standard office visits. The
      anticipated duration of this study is 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local control rate</measure>
    <time_frame>5 years</time_frame>
    <description>Local recurrence is defined as tumor recurrence within the planning target volume. Local control rate will be evaluated by imaging techniques such as CT or MRI. Local recurrence will be defined as an increase of &gt; 20% in tumor size. If necessary, a Positron Emission Tomography scan may be used to aid in diagnoses of local tumor recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>late toxicity rate</measure>
    <time_frame>5 years</time_frame>
    <description>Toxicities will be graded using CTCAE criteria at specified timepoints.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Radiation to Pancreas</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy</intervention_name>
    <description>Suggested fractionation is 20-25 Gy / 1 fraction OR 30-36 Gy / 3 fractions (10-12 Gy per fraction) OR 40-45 Gy / 5 fractions (8-9 Gy per fraction)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age &gt;= 18 years

          -  Performance status of 0-3

          -  Unresectable pancreatic cancer

          -  Maximum tumor diameter &lt; 7.5 cm

          -  Signed study-specific consent form

        Exclusion Criteria:

          -  Maximum tumor diameter &gt; 7.5 cm

          -  Prior radiotherapy to the upper abdomen

          -  Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown
             effects of RT on lactating females

          -  Patients with psychiatric or addictive disorder that would preclude obtaining
             informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. John's Mercy Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 14, 2016</lastchanged_date>
  <firstreceived_date>April 29, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. John's Mercy Research Institute, St. Louis</investigator_affiliation>
    <investigator_full_name>Bethany Sleckman</investigator_full_name>
    <investigator_title>Director Oncology Research</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
